Last reviewed · How we verify
Cutaneous Tcell lymphoma
Approved treatments
- Brentuximab · University of Arizona
- Adcetris · Pfizer
Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cutaneous Tcell lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- Cutaneous Tcell lymphoma treatment landscape brief
- Cutaneous Tcell lymphoma treatment updates RSS
Frequently asked questions about Cutaneous Tcell lymphoma
What drugs treat Cutaneous Tcell lymphoma?
Tracked treatments include Brentuximab, Adcetris.
What is the treatment for Cutaneous Tcell lymphoma?
Standard treatment for Cutaneous Tcell lymphoma includes Brentuximab, Adcetris. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cutaneous Tcell lymphoma patent cliff · Cutaneous Tcell lymphoma CI report
- Treatment: Brentuximab · University of Arizona
- Treatment: Adcetris · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing